

Time Table

Day 1, March 16 (Thu)

<b>Explanatory Notes</b>	<b>AJS</b> = ASCO/JSMO Joint Symposium	<b>SJS</b> = SIOP/JSMO Joint Symposium	<b>EL</b> = Educational Lecture	<b>ME</b> = Meet The Experts	<b>O</b> = Oral Session	<b>PAP</b> = Patient Advocate Program	<b>E</b> = English Session
<b>SL</b> = Special Lecture	<b>APJS</b> = Asia-Pacific/JSMO Joint Symposium	<b>JS</b> = Joint Symposium	<b>PIN</b> = Committee Program 01	<b>MS</b> = Medical Seminar	<b>MO</b> = Mini Oral Session	<b>L</b> = Live Streaming	
<b>AL</b> = Anniversary Lecture	<b>DJS</b> = DIA/JSMO Joint Symposium	<b>PSY</b> = Presidential Symposium	<b>EC</b> = Committee Program 02	<b>MS</b> = Morning Seminar	<b>P</b> = Poster Session	<b>O</b> = On Demand Streaming	
<b>PS</b> = Presidential Session	<b>EJS</b> = ESMO/JSMO Joint Symposium	<b>SY</b> = Symposium	<b>GL</b> = Committee Program 03 · 04	<b>ES</b> = Evening Seminar	<b>HoD</b> = Highlight of the Day	<b>I</b> = Simultaneous Interpretation (E&J)	

		7	8	9	10	11	12	13	14	15	16	17	18	19	
Marine Messe Fukuoka A	Room1 Multi-Purpose Exhibition Hall 1F		Opening Remarks SY01 Future perspectives of molecular targets for GI cancer 8:30-10:00 P.99	PSY01 Current and Future of Financial Toxicity 10:10-11:40 P.99							PS1 Presidential Session 1 Lung cancer/Thoracic Cancer 15:20-17:20 P.100	ES1 The latest treatment strategies in perioperative EGFR-mutated NSCLC 17:35-18:25 P.99			
	Room2 Sub-arena 3F		SY02 Evolution of investigator-initiated registration-directed trials under J-GCP 8:30-10:00 P.102	SY03 Next cancer immunotherapy 10:10-11:40 P.102		MeS2 Nivolumab± Chemo combination therapy ~ Evidence and irAE management~ 12:00-12:50 P.69			O1 Translational Research / Clinical Pharmacology 14:00-15:30 P.103		SY04 Future direction of digital health apps and SaMD (software as medical device) 15:50-17:20 P.104	ES2 CDK 4/6 inhibitor therapy improving breast cancer outcome in early and in metastatic disease P.89			
	Room3 Large Meeting Room 2F		SY05 Treatment for advanced or recurrent cervical cancer: up to date and controversial 8:30-10:00 P.105	O2 Gynecological Cancer 10:10-11:40 P.106		MeS3 Challenges of Cancer Genome Medicine and expectations for a new panel P.69			PSY02 The Present and Future of Drug Development for Asian Rare Cancers in the World 14:00-15:30 P.106		SY06 Considering optimal treatment of premenopausal breast cancer 15:40-17:10 P.107	ES3 The Latest Treatment Strategies in Esophageal Cancer P.89			
Marine Messe Fukuoka B	Room4 Exhibition Hall 1F	EL01 8:30-9:00 Basis of Tumor Immunology P.108	EL02 9:00-9:30 Basic tumor biology (Cancer Genomics) P.108	EL03 9:30-10:00 Impact of Gut Microbiome on Cancer Immunity P.108	EL04 10:15-10:45 Chemotherapy/ Chemotherapeutic agents P.108	EL05 10:45-11:15 Targeted Therapy P.108	EL06 11:15-11:45 Supportive Care in Cancer and Adverse Event Management P.109	MeS4 Treatment strategy for advanced hepatocellular carcinoma in the era of combined immunotherapy P.69	EL07 14:00-14:30 Oncologic emergency and Paraneoplastic syndrome P.109	EL08 14:30-15:00 Usefulness of genetic assessment in cancer treatment for older patients P.109	EL09 15:00-15:30 Palliative care for total pain P.109	EL10 15:40-16:10 Psycho-Oncology / Advance Care Planning P.109	EL11 16:10-16:40 The current status and future direction in the treatment of head and neck cancer and thyroid cancer P.110	EL12 16:40-17:10 Esophageal Cancer and Gastric Cancer P.110	ES4 Management of irAE myocarditis P.89
	Room5 Meeting Room 1 2F		MO1 8:30-9:20 Lung cancer/ Thoracic Cancer1 (IC1) P.111	MO2 9:30-10:20 Lung cancer/ Thoracic Cancer2 (IC2) P.112	MO3 10:30-11:20 Lung cancer/Thoracic Cancer3 (Locally Advanced) P.113		MeS5 Perspective on emerging biomarker-driven therapies in Gastric Cancer P.70	MO4 14:00-14:40 Clinical Trial Facilitation Program 1 (Trials in Progress) P.114	MO5 14:50-15:30 Clinical Trial Facilitation Program2 (Others) P.115	MO6 15:45-16:25 Hepatobiliary / Pancreatic Cancer1 (Hepatocellular carcinoma) P.116	MO7 16:35-17:25 Hepatobiliary / Pancreatic Cancer2 (Biliary tract cancer, Pancreatic cancer) P.117		ES5 Recent Advances in the 1L AIX+ NSCLC treatment Landscape P.90		
	Room6 Meeting Room 2 2F		O3 Multidisciplinary Team Program 8:30-10:00 P.118	PIN JSMO committee on Public Information and Negotiation Program 10:10-11:40 P.119		MeS6 Management of metastatic/ recurrent HER2 positive breast cancer P.70		MO8 14:00-14:50 Breast Cancer1 (Perioperative/ Others1) P.119	MO9 14:50-15:40 Breast Cancer2 (Perioperative/ Others2) P.120	MO10 15:45-16:35 Cross-sectional Program1 (Genome, Imaging diagnosis) P.121	MO11 16:35-17:25 Cross-sectional Program2 P.122		ES6 The Usefulness of the NGS Panel Test in Lung Cancer Treatment P.90		
Fukuoka International Congress Center	Room7 Main Hall 3F		EC Oncology Education Initiatives at Medical Oncology Society in the Asia-Pacific Region 8:30-10:00 P.123	AJS Emerging novel therapy (including new generation CAR-T, BITE, cancer RNA vaccine) 10:10-11:40 P.123		MeS7 The future treatment strategies to improve prognosis in EGFR+ NSCLC P.70		SY07 Update to Strategies for the Treatment of NSCLC with Driver Gene Mutation 13:50-15:20 P.124		JS01 Cancer Genomic Medicine and Beyond 15:40-17:10 P.125		ES7 Management of renal disorder associated with cancer pharmacological therapy and selection of appropriate treatment P.90			
	Room8 201+202 2F		SY08 Reviewing the role of proper use of genetic alteration specific / tumor - agnostic driven anti-cancer drugs and cancer genomic panel testings 8:30-10:00 P.126	O4 Gastrointestinal Cancer1 (Colorectal cancer) 10:10-11:40 P.126		MeS8 How to Treat Cancer of Unknown Primary - How to use Opdivo, the first anticancer drug covered by insurance for CLP 7 ~ P.70		MO12 14:00-14:50 Hematologic Malignancies (CLL, Lymphoma) P.127	GL03 14:55-15:40 Overview of Oncocardiology guideline P.128	GL04 15:50-17:20 Part1: Overview of JSMO Cancer Immunotherapy Guideline, Third Edition / Part2: Molecular Testing for Colorectal Cancer Treatment: Key points of the revision P.128		ES8 Minimal residual disease assessment in aggressive B-cell lymphoma P.91			
	Room9 203+204 2F		SY09 Individualizing Adjuvant Therapy in patients with HER2-negative breast cancer 8:30-10:00 P.130	O5 Patient Advocacy 10:10-11:40 P.130		MeS9 Comprehensive Treatment Sequence in metastatic Gastric Cancer since the Introduction of ICI in first-line Treatment P.71		PSY03 Future perspectives of emerging therapies for gastroesophageal adenocarcinoma 14:00-15:30 P.131		O6 Cross-sectional Program 15:40-16:55 P.132		ES9 Tumor burden monitoring for cancer therapy with circulating tumor DNA using a digital PCR probe library P.91			
	Room10 409+410 4F		MO13 8:30-9:20 Translational Research / Clinical Pharmacology (Basic Research) P.133	MO14 9:30-10:20 Translational Research / Clinical Pharmacology (Predictive factor of molecular-targeted therapy) P.134	MO15 10:30-11:20 Translational Research / Clinical Pharmacology (Genomic Medicine) P.135		MeS10 Guardant360-guided Precision Oncology P.71	MO16 14:00-14:50 Gastrointestinal Cancer1 (Colorectal Cancer Biomarker) P.136	MO17 14:50-15:40 Gastrointestinal Cancer2 (Colorectal Cancer vulnerable) P.137	MO18 15:40-16:40 Gastrointestinal Cancer3 (Colorectal Cancer, Chemotherapy) P.138	MO19 16:40-17:30 Gastrointestinal Cancer4 (Esophageal Cancer, Chemotherapy) P.139		ES10 G-CSF Up-to-Date P.91		
	Room11 411+412 4F		MO20 8:30-9:20 Rare Cancer4 (Sarcoma1) P.140	MO21 9:30-10:20 Rare Cancer5 (Sarcoma2) P.141	MO22 10:30-11:20 Rare Cancer6 (Central Nervous System Tumors1) P.141		MeS11 Treatment Strategy of relapsed/refractory follicular lymphoma P.71	MO23 14:00-14:50 Rare Cancer7 (Central Nervous System Tumors2) P.142		PS1 Presidential Session 1 Live Webcast 15:20-17:20		ES11 Transition of treatment development in lung cancer P.92			
	Room12 501 5F		SY10 Secondary cancers in cancer survivors: challenges and how to face late complications 8:30-10:00 P.144	JS02 Symptom Management of Bone Metastases 10:10-11:40 P.144		MeS12 Topics of immunotherapy for recurrent or metastatic head and neck cancer in clinical practice P.71		PSY04 Educational Training for Patient Advocates: Current Status and Issues in Japan 14:00-15:30 P.146		SY11 Shall we discuss the future perspective of combined immunotherapy multidirectionally? 15:40-17:10 P.147		ES12 Update on the Treatment of Gastric Cancer P.92			
	Room13 502+503 5F		MO24 8:30-9:20 Genitourinary Cancer1 (Prostate cancer) P.148	MO25 9:30-10:20 Genitourinary Cancer2 (Renal cancer) P.148	MO26 10:30-11:20 Multidisciplinary Team Program (Healthcare team 1) P.149		MeS13 Onco-Cardiology - Cooperation between Hematology and Cardiology P.72	MO27 14:00-14:50 Palliative Care / Symptom Management1 P.150	MO28 14:50-15:40 Palliative Care / Symptom Management2 P.151	MO29 15:45-16:25 Patient Advocacy / Survivorship (Adolescent and Young Adult) P.152	MO30 16:35-17:15 Patient Advocacy / Survivorship (Geriatric Oncology, APC) P.153		ES13 Recent advances in perioperative drug therapy in lung cancer. P.92		
	Meet the Experts ① 401 4F		ME01 8:30-9:30 New developments in B cell lymphoma P.154		ME02 10:30-11:30 Treatment of targeted therapy induced drug persistent disease P.154			ME03 14:00-15:00 HER2 positive breast cancer: Update and new drugs on the horizon P.154		ME04 16:00-17:00 Novel immunotherapy combinational approach in advanced oesophago-gastric adenocarcinoma P.154					
	Meet the Experts ② 402 4F				ME05 10:30-11:30 Evolving Landscape of Systemic Therapy for Advanced Hepatocellular Carcinoma P.155			ME06 14:00-15:00 Side effect and symptom management in breast cancer patients P.155		ME07 16:00-17:00 Management of Women with Advanced and Recurrent Gynecologic Malignancies P.155					
	Marine Messe Fukuoka B	PAP Room Exhibition Room 1/2 1F			PAP Basic Lecture ① 10:10-10:55 P.58		PAP Basic Lecture ② 11:00-11:45 P.58		PAP Luncheon Seminar ① 12:00-12:50 P.58		PAP Basic Lecture ③ 14:00-14:45 P.58	PAP Basic Lecture ④ 14:45-15:30 P.58	PAP Basic Lecture ⑤ 15:45-16:30 P.58	PAP Basic Lecture ⑥ 16:30-17:15 P.59	
Marine Messe Fukuoka A	Poster Room Multi-Purpose Exhibition Hall 1F		8:00-8:30 Putting Up Posters	Poster Display				8:30-13:05	13:05-13:50 Poster Session P.156	Poster Display				13:50-17:15	17:15-17:45 Poster Removal

Time Table

Day 2, March 17 (Fri)

<b>Explanatory Notes</b>	<b>AJS</b> = ASCO/JSMO Joint Symposium	<b>SJS</b> = SIOP/JSMO Joint Symposium	<b>EL</b> = Educational Lecture	<b>ME</b> = Meet The Experts	<b>O</b> = Oral Session	<b>PAP</b> = Patient Advocate Program	<b>E</b> = English Session
<b>SL</b> = Special Lecture	<b>APJS</b> = Asia-Pacific/JSMO Joint Symposium	<b>JS</b> = Joint Symposium	<b>PIN</b> = Committee Program 01	<b>MEs</b> = Medical Seminar	<b>MO</b> = Mini Oral Session	<b>L</b> = Live Streaming	
<b>AL</b> = Anniversary Lecture	<b>DJS</b> = DIA/JSMO Joint Symposium	<b>PSY</b> = Presidential Symposium	<b>EC</b> = Committee Program 02	<b>MeS</b> = Morning Seminar	<b>P</b> = Poster Session	<b>O</b> = On Demand Streaming	
<b>PS</b> = Presidential Session	<b>EJS</b> = ESMO/JSMO Joint Symposium	<b>SY</b> = Symposium	<b>GL</b> = Committee Program 03-04	<b>ES</b> = Evening Seminar	<b>HoD</b> = Highlight of the Day	<b>I</b> = Simultaneous Interpretation (E&J)	

		7	8	9	10	11	12	13	14	15	16	17	18	19		
Marine Messe Fukuoka A	Room1 Multi-Purpose Exhibition Hall 1F	7:20-8:10 MeS1 Drug loss in Oncology and Japan decline P.80	HoD1 Highlight of the Day 1 P.181	SL 10:15-11:15 Balancing Architectural Works and Social Contributions P.181	MeS14 Rethinking EGFR Mutation-Positive Lung Cancer P.72	社員総会 12:35-13:25 表彰式 13:35-13:55		AL 14:00-15:10 Part 1: 20th Anniversary Ceremony Part 2: Anniversary Lecture P.182			PS2 Presidential Session 2 Breast Cancer P.182	ES14 Optimized adjuvant treatment strategy for HER2 negative early breast cancer. P.93				
	Room2 Sub-arena 3F	MeS2 Current status of Immune Checkpoint Inhibitor for NSCLC ~ Perioperative and Advanced or Metastatic ~ P.81	O7 Lung cancer/Thoracic Cancer1 (NSCLC) P.184	MO31 Lung cancer/Thoracic Cancer4 (Biomarker) P.185	MeS15 Genomics and Immunotherapy Making Matched Targeted Combination Approach a Clinical Reality P.72					MO32 Translational Research / Clinical Pharmacology (multi-gene panel testing) P.186	SY12 PD-L1 testing and biomarkers for immune checkpoint blockade P.187	ES15 Cancer genomic medicine moving forward P.93				
	Room3 Large Meeting Room 2F	MeS3 Combat the Diversity of EGFR mutations ~ Considerations about Treatment Strategy for EGFR-positive non-small cell lung cancer ~ P.81	SY13 First-line therapy for advanced renal cell cancer P.188	MO33 Genitourinary Cancer3 (Urothelial cancer) P.188	MeS16 Correlation between genotype and phenotype - Causative genes and appearance of hereditary cancer - P.73					MO34 Hepatobiliary / Pancreatic Cancer3 (Pancreatic cancer, Hepatocellular carcinoma) P.189	SY14 New developments in systemic therapy for pancreatic cancer P.190	ES16 Front line of personalized therapy for colorectal cancer P.93				
Marine Messe Fukuoka B	Room4 Exhibition Hall 1F	MeS4 Revision of the Practical Guideline of Bone Metastasis 2022 - Reconsideration of significance of antibody ability in cancer patients P.81	EL13 Colorectal cancer and small bowel cancer P.191	EL14 Chemotherapy of Bladder Cancer and Pancreatic Cancer P.191	EL15 Chemotherapy of Bladder Cancer and Pancreatic Cancer P.191	EL16 Chemotherapy of Bladder Cancer and Pancreatic Cancer P.191	EL17 Standard treatment for ovarian cancer and endometrial cancer P.192	EL18 Systemic therapy for genitourinary cancers P.192	MeS17 Best practices for late line treatment in mCRC P.73	EL19 Conflicts of Interest Management for Clinical Research P.192	EL20 Small cell lung cancer and malignant mesothelioma P.192	EL21 Updates of JAVELIN Bladder 100 and latest clinical trials in metastatic urothelial carcinoma P.94	EL22 Breast cancer (Neo / Adjuvant chemotherapy) P.193	EL23 Breast cancer management for recurrent breast cancer P.193		
	Room5 Meeting Room 1 2F	MeS5 Precision Medicine in Leukemia P.81	PS3 Presidential Session 3 Live Webcast P.197	MO35 Lung cancer/Thoracic Cancer5 (Molecular-targeted therapy1) P.194	MeS18 What is and will be the optimal strategy following 1st line CDK4/6 inhibitor for HR-positive/HER2-negative metastatic breast cancer? P.73					MO36 Rare Cancer2 (Cancer of Unknown Primary, Malignant melanoma) P.195	SY15 Advances in the treatments of rare cancers P.196	ES18 Therapeutic Strategies for AML with FLT3 Mutation P.94				
	Room6 Meeting Room 2 2F	MeS6 Positioning Lutathera in the multidisciplinary treatment of GEP-NET P.82	O8 Palliative Care / Symptom Management P.197	JS03 New developments in targeted radionuclide therapy P.198	MeS19 Best Practice for Colorectal Cancer Pharmacotherapy P.74					MO37 Tumor-agnostic therapy for NTRK fusion-positive solid tumors - Focusing on genomic medicine for sarcoma in Japan and Global- P.94	SY16 Basic knowledge and recent trends of novel oncology drug developmental therapeutics - "Focused" / "Spotlighted" New Drugs P.199	ES19 Considering Treatment with Immune Checkpoint Inhibitors for Advanced NSCLC P.95				
Fukuoka International Congress Center	Room7 Main Hall 3F	MeS7 Genomics-Based Personalized Colorectal Cancer Treatments P.82	PS4 Presidential Session 3 Miscellaneous P.201	MeS20 Scientific Exchange Meeting 2023 Advances in Systemic Therapy for Biliary Tract Cancers from TOPAZ-1 to Targeted Therapies P.74							MO38 Lung cancer/Thoracic Cancer6 (Molecular-targeted therapy2) P.202	EJS Cutting-edge precision oncology (including ctDNA/RNA, WGS/WES, multi-omics analyses) P.203	ES20 Results from TRANSFORM study and implementation of CD19 CAR-T cell treatments in 2L R/R BLCL P.95			
	Room8 201+202 2F	MeS8 Financial Toxicity in Japanese Cancer Treatment: Facts and Measures to Manage the Problem. P.83	SY17 Current status of therapeutic development for gastroenteropancreatic neuroendocrine neoplasms P.204	O9 Head and Neck Cancer P.204	MeS21 The Perspectives of Personalized Medicine in Gastric Cancer P.74					MO39 Gastrointestinal Cancer6 (Gastric Cancer, Geriatric/ Perioperative) P.205	SY18 How to manage the 1st line chemotherapy for esophageal cancer? P.206	ES21 How to maximize necitumab in the age of immunotherapy ~ beyond the immunotherapy ~ P.95				
	Room9 203+204 2F	MeS9 Treatment Strategy for Non-Small Cell Lung Cancer 2023 - Focusing on Atezolizumab P.83	DJS Novel International Clinical Research Design and its Regulation P.207	MO40 Gastrointestinal Cancer5 (Esophageal Cancer, Perioperative Treatment) P.207	MeS22 The perspectives on the treatment of early Triple Negative Breast Cancer P.74					O10 Lung cancer/Thoracic Cancer2 (NSCLC, Others) P.208		ES22 Optimal driver gene diagnosis and ALU-positive lung cancer treatment discussing with Japanese and American physicians P.96				
	Room10 409+410 4F	MeS10 The role of anti-EGFR antibodies in metastatic colorectal cancer P.83	O11 Breast Cancer P.210	MO41 Breast Cancer3 (Biomarker) P.210	MeS23 Treatment sequence and new therapeutic options in advanced PDAC P.75					MO42 Rare Cancer1 (Thyroid Cancer, Germ Cell Tumor) P.211	SY19 Optimal Treatment Strategy for Head and Neck Cancer in the Era of Immunotherapy - Current Evidence and Future Directions - P.212	ES23 Management of metastatic TNBC: latest advances and future directions P.96				
	Room11 411+412 4F	MeS11 Toward Clinical Introduction of idyllia™ System ~ Aiming to Shorten Turnaround time of Genetic Testing ~ P.84	MO43 Head and Neck Cancer1 P.213	MO44 Head and Neck Cancer2 P.214	MO45 Multidisciplinary Team Program (Healthcare team 2) P.214	MeS24 The first line chemotherapy of esophageal cancer: How can we achieve long-term survival? P.75					PS2 Presidential Session 2 Live Webcast P.222	ES24 How I Treat AML in 2023: A US Perspective P.96				
	Room12 501 5F	MeS12 New treatment perspective in HER2 positive metastatic breast cancer - Enhentu Brings a Bright Future- P.84	SY20 Evidence and Practice of Advance Care Planning P.216	MO46 Palliative Care / Symptom Management3 P.216	MeS25 European and Asian treatment strategies for recurrent/metastatic head and neck cancer - Focus on the contents of ESMO Guideline - P.75					MO47 Multidisciplinary Team Program (Healthcare team 3) P.217	SY21 How to support elderly cancer patients through multidisciplinary collaboration P.218	ES25 How I Treat AML in 2023: A US Perspective P.96				
	Room13 502+503 5F	MeS13 Current status and future prospects of genomic medicine in hematologic malignancies P.84	MO48 Hematologic Malignancies (AML, ALL, Transplantation) P.220	MO49 Hematologic Malignancies (Lymphoma) P.221	MO50 Hematologic Malignancies (Others) P.222	MeS26 Team-based medical care + Kampo P.76					MO51 COVID-19 1 P.222	SY22 New molecular target therapies based on genome sequencing P.223	ES26 Supportive Care Advancing Cancer Treatment P.96			
	Meet the Experts ① 401 4F		ME08 Recent progress and emerging issues in advanced treatment of resectable locally advanced gastric cancer P.225	ME09 Cancer Patient Advocacy, The Future, and Challenges P.225							ME10 Impact of the NETSARC network of reference centers for the diagnosis and treatment of sarcomas in France since 2010 P.225					
	Meet the Experts ② 402 4F		ME11 How to overcome and circumvent acquired resistance to osimertinib or lazertinib in advanced EGFR mutant lung cancer? P.226	ME12 Clinical Trial Facilitation Program P.226								ME13 Existing controversies in bladder and kidney cancer P.226				
	Marine Messe Fukuoka B	PAP Room Exhibition Room 1/2 1F	PAP Basic Lecture ⑦ P.59	PAP Basic Lecture ⑧ P.59	PAP Basic Lecture ⑨ P.59	PAP Luncheon Seminar ② P.59					PAP Basic Lecture ⑩ P.59					
Marine Messe Fukuoka A	Poster Room Multi-Purpose Exhibition Hall 1F	Poster Display												Poster Session P.227	Poster Display	Poster Removal

Time Table

Day 3, March 18 (Sat)

<b>Explanatory Notes</b>	<b>AJS</b> = ASCO/JSMO Joint Symposium	<b>SJS</b> = SIOP/JSMO Joint Symposium	<b>EL</b> = Educational Lecture	<b>ME</b> = Meet The Experts	<b>O</b> = Oral Session	<b>PAP</b> = Patient Advocate Program	<b>E</b> = English Session
<b>SL</b> = Special Lecture	<b>APJS</b> = Asia-Pacific/JSMO Joint Symposium	<b>JS</b> = Joint Symposium	<b>PIN</b> = Committee Program 01	<b>MS</b> = Medical Seminar	<b>MO</b> = Mini Oral Session	<b>L</b> = Live Streaming	
<b>AL</b> = Anniversary Lecture	<b>DJS</b> = DIA/JSMO Joint Symposium	<b>PSY</b> = Presidential Symposium	<b>EC</b> = Committee Program 02	<b>MS</b> = Morning Seminar	<b>P</b> = Poster Session	<b>OS</b> = On Demand Streaming	
<b>PS</b> = Presidential Session	<b>EJS</b> = ESMO/JSMO Joint Symposium	<b>SY</b> = Symposium	<b>GL</b> = Committee Program 03-04	<b>ES</b> = Evening Seminar	<b>HoD</b> = Highlight of the Day	<b>SI</b> = Simultaneous Interpretation (E&J)	

		7	8	9	10	11	12	13	14	15	16	17	18	19	
Marine Messe Fukuoka A	Room1 Multi-Purpose Exhibition Hall 1F			HoD2 Highlight of the Day 2 8:30-9:40 P.255	PS4 Presidential Session 4 Gastrointestinal Cancer 9:45-11:45 P.255		MeS27 Expectation for gastric cancer 1st line treatment by CA 649 long term follow up data / Progress and future in the treatment of advanced gastric cancer P.76			HoD3 Highlight of the Day 3 14:00-16:30 P.256					
	Room2 Sub-arena 3F		MoS14 Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy P.85	SY23 Future perspective of antibody-drug conjugate (ADC) for various cancer 8:30-10:00 P.258	SY24 Hope and future: perspectives on complex innovative design 10:10-11:40 P.258		MeS28 Applying 'Judicious' Immunotherapy (AIPI)+MUDCO-Chemotherapy in Clinical Practice P.76		SY25 Tumor-agnostic clinical questions in the recent medical oncology field 14:00-15:30 P.259	MO52 Cross-sectional Program4 (Others) 15:40-16:30 P.259					
	Room3 Large Meeting Room 2F		MoS15 Up-to-date treatment for mCRC ~ Treatment strategies considering Fit/Vulnerable~ P.85		MO33 Genitourinary Cancer4 (Others) 9:10-9:50 P.261	O12 Genitourinary Cancer 10:10-11:25 P.262		MeS29 Key points of Adlumiz introduction for cancer cachexia P.77		PSY05 Career empowerment plans in JSMO 14:00-15:30 P.263	MO54 COVID-19 2 15:30-16:30 P.263				
Marine Messe Fukuoka B	Room4 Exhibition Hall 1F		MoS16 Why now is the relevant time to review Imbriz safety ~ Taking PIVS and other RWGS into account ~ P.86	EL24 bone and soft tissue tumors 8:30-9:00 P.265	EL25 Recent Advances in the Treatment of Malignant Lymphoma 9:00-9:30 P.265	EL26 Leukemia Treatment by Oncologists in Outpatient Settings 9:30-10:00 P.265	EL27 AJCC treatment algorithm for multiple myeloma - a review 10:10-10:40 P.265	EL28 New Venetoclax regimen ~ CD38 agonist (stromal) ~ 10:40-11:10 P.265	EL29 Skin Cancer 11:10-11:40 P.266		EL30 Therapeutic strategy for primary unknown cancer (CLP) 14:00-14:30 P.266	EL31 Pediatric Cancer 14:30-15:00 P.266	EL32 Current Status of Precision Oncology in Japan 15:00-15:30 P.266	EL33 Primary brain tumor, metastatic brain tumor 15:30-16:00 P.266	EL34 Clinical trials act / Personal Data Protection 16:00-16:30 P.267
	Room5 Meeting Room 1 2F		MoS17 Treatment of Mantle Cell Lymphoma ~ Current Status and Future Prospects ~ P.86	MO55 Lung cancer/ Thoracic Cancer7 (Metastatic) 9:30-10:20 P.268	MO56 Lung cancer/ Thoracic Cancer8 9:30-10:20 P.269	MO57 Lung cancer/ Thoracic Cancer9 10:35-11:25 P.270		MeS30 To provide effective drug, surely for patients ~ our current situation in a hospital without pathologists ~ (Current Evidence of KRAS Mutator-Positive Lung Cancer P.77		MO58 Breast Cancer4 (Metastatic1) 14:00-14:50 P.271	MO59 Breast Cancer5 (Metastatic2) 15:00-15:40 P.272				
	Room6 Meeting Room 2 2F		MoS18 Treatment strategy targeting the Tumor Immune Micro Environment (TIME) in Multiple Myeloma : Immune-based Therapy P.86	O13 Hematologic Malignancies 8:30-10:00 P.273	SY26 Immune and cell therapy for hematologic malignancies 10:10-11:40 P.273		MeS32 Current and Future Treatment Landscape for DLBCL P.78		MO60 Hepatobiliary / Pancreatic Cancer4 (Pancreatic cancer, Biomarker) 14:00-15:00 P.274	MO61 Hepatobiliary / Pancreatic Cancer5 (Pancreatic cancer) 15:00-15:50 P.275					
Fukuoka International Congress Center	Room7 Main Hall 3F		MoS25 Immunotherapy for the Treatment of Triple Negative Breast Cancer in Metastatic and Early Stage Disease: Application to the Clinic P.87	APJS Digital transformation in clinical practice and trials (including telemedicine, eConsent/ePRO) 8:30-10:00 P.277	SJS Geriatric oncology in the world 10:10-11:40 P.277		MeS33 Development of novel treatment strategy for advanced lung cancer - Targeted therapy and Immunotherapy - P.78		MO62 Lung cancer/ Thoracic Cancer10 14:00-15:00 P.278	SY27 Perioperative treatment reloaded: role of immune checkpoint inhibitors and targeted therapies 15:00-16:30 P.279					
	Room8 201+202 2F		MoS19 Transition to cancer pain management of breakthrough cancer pain especially in the settings where there is specialized palliative care service or strong opioids. P.87	O14 Gastrointestinal Cancer2 (Esophageal Cancer, Gastric Cancer, GIST) 8:30-9:45 P.280	MO63 Gastrointestinal Cancer7 (Esophageal Cancer, Gastric Cancer, ICI) 10:10-10:50 P.281		MeS34 Significance of FGFR inhibitors in biliary tract cancer and management of their adverse events - focusing on skin and nail toxicity P.78		MO64 Gastrointestinal Cancer8 (Gastric Cancer, Developmental Therapeutics, Biomarker) 14:00-14:50 P.282	MO65 Gastrointestinal Cancer9 (Gastric Cancer, Biomarker) 14:50-15:40 P.283	MO66 Gastrointestinal Cancer10 (Gastrointestinal Cancer, Biomarker) 15:40-16:30 P.284				
	Room9 203+204 2F		MoS20 Next Step of diagnosis and treatment for NSCLC harboring driver gene alterations P.87	JS04 Anti-cancer medicine and cardiovascular adverse events 8:30-10:00 P.285	JS05 Tips for genetic medicine encountered in precision oncology 10:10-11:40 P.286		MeS35 Considering personalized treatment of ALK/ROS1-positive lung cancer P.79		O15 Hepatobiliary / Pancreatic Cancer 14:00-15:50 P.286						
	Room10 409+410 4F		MoS21 Risk management of the Tumor lysis syndrome ~ Focus on Hematological Malignancies ~ P.87	O16 Rare Cancer 8:30-10:40 P.288	MO67 Patient Advocacy / Survivorship (Others) 10:40-11:30 P.289		MeS36 Mantle Cell Lymphoma - current treatment standards & new options P.79			MO68 Translational Research / Clinical Pharmacology (immunotherapy) 15:40-16:30 P.290					
	Room11 411+412 4F		MoS22 Essential Rules for Success in Cancer Precision Medicine P.88	MO69 Rare Cancer3 (NET/NEC) 8:30-9:20 P.291	PS4 Presidential Session 4 Live Webcast 9:45-11:45		MeS37 Patient Journey in Thyroid Cancer and Genetic Testing in Solid Tumors P.79		Medical Oncology Seminar 14:00-18:00						
	Room12 501 5F		MoS23 What oncologists need to know about pain relief for cancer patients ~ How to successfully use weak opioid analgesics ~ P.88	JS06 Implementing Patients' Voices to the Field: Challenges and Future of Qualitative Research 8:30-10:00 P.292	SY28 Future Prospects for Treatment of Cancer Cachexia 10:10-11:40 P.293		MeS38 Current status and future of chemotherapy induced hair loss reduction effect by scalp cooling system P.80		SY29 Essence of Guidelines for Psychiatric Symptoms in Cancer Care 14:00-15:30 P.294	MO70 Palliative Care / Symptom Management4 15:40-16:30 P.294					
	Room13 502+503 5F		MoS24 Treatment strategies for untreated classical Hodgkin Lymphoma P.88	MO71 Gynecological Cancer 8:30-9:35 P.296	MO72 Access to Medicines 9:35-10:25 P.297	O17 Clinical Trial Facilitation Program 10:25-11:40 P.297		MeS39 Science and treatment strategy for patients with HER2+ AGC P.80		Advanced Seminar for CRC (Japan Society of Clinical Trials and Research) 14:00-16:30					
	Meet the Experts ① 401 4F			ME14 The Significance of Team Medicine in Promoting Appropriate Use of ICI 8:30-9:30 P.299		ME15 Tumor-agnostic precision drug development and approval: A novel platform - where do we go - ? 10:30-11:30 P.299			ME16 Facts and Hopes for Gut Microbiota Interventions in Cancer Immunotherapy 14:00-15:00 P.299	ME17 How do you treat uncommon head and neck cancer in the era of cancer genome medicine? 15:30-16:30 P.299					
	Meet the Experts ② 402 4F														
	Marine Messe Fukuoka B	PAP Room Exhibition Room 1/2 1F		PAP PAP Applied Lecture ① 8:30-9:20 P.59	PAP PAP Applied Lecture ② 9:30-10:20 P.59	PAP PAP Applied Lecture ③ 10:30-11:20 P.59		PAP Luncheon Seminar ③ 12:00-12:50 P.60		PAP PAP Applied Lecture ④ 14:00-16:10 P.60					
Marine Messe Fukuoka A	Poster Room Multi-Purpose Exhibition Hall 1F		8:00-8:30 Putting Up Posters	Poster Display			8:30-13:05 Poster Session P.300	13:05-13:50 Poster Removal	13:50-14:20 Poster Removal						